APVO — Q2 2026 Financial Report Analysis

Aptevo's Q2 2026: steady spending, a $6.4 million quarterly loss, and only $9.8 million of cash left

Aptevo Therapeutics is a clinical-stage cancer drug developer: it has no products on the market and no revenue, so its quarterly results are really a report on how fast it spends money and how long that money lasts. In the second quarter of 2026 it lost $6.4 million, almost the same as a year earlier ($6.2 million), as more spending on its lead leukemia drug mipletamig was partly offset by lower overhead. The bigger story is the balance sheet: cash fell to $9.8 million from $21.6 million at the start of the year, and the company itself says there is "substantial doubt" it can keep operating for another year without raising more money.

At a glance

• $9.8 million cash vs. $13.4 million burned in six months. At the first-half pace (about $2.2 million a month), the June cash pile covers roughly four and a half months of operations on its own.
• Net loss of $6.4 million, 2.4% wider than a year ago. Spending on mipletamig rose 31% to $2.0 million in the quarter; general overhead fell 5%.
• Loss per share fell from $151.29 to $5.31 — but not because the business improved. The average share count rose about 29-fold (after heavy share issuance and two reverse stock splits), so the same-sized loss is spread over far more shares.

The numbers

Figures from the condensed consolidated statements in Aptevo's Form 10-Q for the quarter ended June 30, 2026. Share and per-share amounts are restated for the 1-for-20 reverse split of May 2025 and the 1-for-18 reverse split of December 2025. "n/m" = not meaningful.

Where the money went

Research and development (R&D) — the cost of lab work, manufacturing trial drug and running clinical trials — rose $0.4 million to $3.7 million. The filing attributes the increase to "higher mipletamig clinical study costs, preclinical projects testing costs, and consulting fees, offset by lower costs on ALG.APV-527." The program table shows how concentrated the spending has become:

Mipletamig is a "T cell engager" — an antibody-like molecule built to bind the CD123 marker on leukemia cells and the CD3 marker on the patient's own immune T cells, pulling the two together so the T cells attack the cancer. It is being tested in the Phase 1b/2 RAINIER trial in newly diagnosed acute myeloid leukemia (AML) patients too frail for intensive chemotherapy, added on top of the standard venetoclax + azacitidine regimen. ALG.APV-527, partnered 50/50 with Alligator Bioscience, finished its first-in-human study and now accounts for only a sliver of spending ($48,000 in the quarter).

General and administrative (G&A) costs — executive, finance, legal and office overhead — fell $0.2 million to $2.7 million, which the filing attributes to "lower employee costs." Interest income on cash added $0.09 million.

What the headline numbers hide

• Cash burn runs slightly ahead of the accounting loss. Over six months, operating activities used $13.4 million versus a net loss of $13.1 million. Very little of the loss is non-cash (stock-based compensation was only $0.1 million), and the company also paid down $1.1 million of accrued bills. For a company like this, the cash line is the one to watch.
• No adjusted figures to reconcile. The 10-Q presents only GAAP (standard accounting) results, so there is no gap between "headline" and "adjusted" loss.
• Small accounting one-off from warrants. In the first quarter, a $97,000 "dividend attributable to down round feature of warrants" — an accounting charge recorded when the exercise price of some older warrants reset lower after new shares were sold cheaply — lifted the six-month loss attributable to shareholders to $13.15 million from a net loss of $13.05 million. Not material in size, but a reminder that each financing re-prices earlier ones.
• The loss-per-share "improvement" is entirely dilution. The quarterly loss was essentially flat in dollars, while weighted shares went from about 41,000 to about 1.2 million. Comparing per-share figures across years tells you nothing about operations here.
• Shareholders face much more dilution ahead. At June 30 there were 1.42 million shares outstanding. As of August 13 there were about 6.06 million warrants (rights to buy shares at a fixed price) outstanding, including 5.58 million new ones at $4.03 a share issued in an August financing. Those became exercisable after stockholders approved the issuance on September 22, 2026. Outstanding warrants are more than four times the June 30 share count, so full exercise would multiply the number of shares several-fold.
• No receivables, inventory or buybacks to examine — the company has no sales, and it is issuing shares, not buying them back.

The funding squeeze

The filing is explicit that existing cash "is not expected to be sufficient to fund operations for at least one year," and management and the board conclude there is substantial doubt about the company's ability to continue as a "going concern" (accounting language for staying in business for the next 12 months).

What changed after the quarter:

• Raised about $5 million more. On August 12, Aptevo sold 861,708 shares (or pre-funded warrants) at $4.03 in a private placement and persuaded holders of older warrants to exercise 254,922 of them at a reduced $4.03, for $4.5 million gross, before fees. It also sold another $0.6 million of stock to Yorkville under its standby equity facility after the quarter.
• But gave up its two easiest sources of cash for a year. As part of that deal, Aptevo agreed not to use its Yorkville standby equity purchase agreements (which still had $66.8 million of nominal capacity at June 30) or its at-the-market share sales program with Roth until 12 months after stockholder approval — and that approval came on September 22, 2026. So both are effectively off the table until around September 2027.
• The new warrants are now the main lever. Exercise of all the $4.03 August warrants would bring in about $22.5 million, according to the filing's warrant table — but holders will only exercise if the share price is comfortably above $4.03.

Adding the roughly $5 million raised after June 30 to the $9.8 million in hand gives about $15 million before fees, or roughly six to seven months at the first-half burn rate. Other possible inflows are small or uncertain: up to $5.8 million in milestone payments from Medexus tied to sales of IXINITY (a hemophilia product Aptevo sold in 2020), a $1.5 million Washington State research grant paid as reimbursement for APVO451 work through June 2028, and Niowave's right to buy up to 97,373 more shares.

Takeaway: Aptevo's operating spend is stable at $6.4–6.8 million a quarter, so the quarter itself held no surprise; what matters is that cash covered only about four to five months of that spending at June 30, and the August financing that added about $5 million also locked away the company's standby equity line and at-the-market program until roughly September 2027. Whether mipletamig's trial data can lift the share price above the $4.03 warrant price — turning up to $22.5 million of warrants into cash — is now the company's main funding route.

What to watch next

• RAINIER data and regulatory talks. In a September 3, 2026 press release (filed on Form 8-K), Aptevo reported that 13 of 14 evaluable patients with TP53-mutated AML — one of the hardest forms of the disease to treat — saw "clinical benefit" on the mipletamig triplet, and 11 (79%) reached complete remission or complete remission with incomplete blood-count recovery. The company compares that with a published 41% remission rate for venetoclax + azacitidine alone in a similar group. That is a small, open-label (unblinded, no control group) sample and a cross-trial comparison, so it is encouraging but not proof. The company expects the dose-optimization part of the trial to finish by year-end 2026 and plans to meet regulators in the first half of 2027 to decide next steps.
• New programs. A 50/50 collaboration with Niowave (signed May 25, 2026) on up to three radiopharmaceutical cancer drugs, and APVO451, a trispecific antibody aimed at the nectin-4 tumor marker, which the company expects to move into IND-enabling studies (the safety work needed before human trials) in the first half of 2027.
• Nasdaq listing. Aptevo has done reverse stock splits in May 2025 and December 2025; the filing notes that because of the recent split, a renewed fall below $1.00 per share for 30 business days would mean immediate delisting proceedings with no 180-day grace period.
• Q3 2026 10-Q (expected around mid-November). The key numbers will be quarter-end cash and how many of the $4.03 warrants have been exercised.

Our read: with spending this steady, the trajectory is set almost entirely by financing. Absent meaningful warrant exercises or a partnering deal for mipletamig, Aptevo is likely to need another raise in the first half of 2027, around the same time it hopes to have regulatory feedback — which would leave existing shareholders exposed to further dilution at whatever price the data supports.